Bulletin
Investor Alert

New York Markets Close in:

AstraZeneca PLC ADR

NAS: AZN

GO
/marketstate/country/us

Market open

 --Real time quotes

Sep 20, 2021, 11:32 a.m.

AZN
/zigman2/quotes/200304487/composite

$

58.50

Change

+2.94 +5.28%

Volume

Volume 7.42m

Real time quotes

/zigman2/quotes/200304487/composite

Previous close

$ 55.56

$ 58.50

Change

+2.94 +5.28%

Day low

Day high

$56.08

$58.50

Open

52 week low

52 week high

$46.48

$60.93

Open

Company Description

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquart...

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Valuation

P/E Current

42.48

P/E Ratio (with extraordinary items)

38.04

P/E Ratio (without extraordinary items)

38.56

Price to Sales Ratio

4.47

Price to Book Ratio

8.41

Price to Cash Flow Ratio

25.45

Enterprise Value to EBITDA

17.80

Enterprise Value to Sales

4.89

Total Debt to Enterprise Value

0.14

Efficiency

Revenue/Employee

282,763.00

Income Per Employee

32,750.00

Receivables Turnover

5.35

Total Asset Turnover

0.45

Liquidity

Current Ratio

0.96

Quick Ratio

0.76

Cash Ratio

0.39

Profitability

Gross Margin

74.01

Operating Margin

16.98

Pretax Margin

14.29

Net Margin

11.58

Return on Assets

5.24

Return on Equity

23.36

Return on Total Capital

14.29

Return on Invested Capital

10.66

Capital Structure

Total Debt to Total Equity

130.46

Total Debt to Total Capital

56.61

Total Debt to Total Assets

30.54

Long-Term Debt to Equity

115.18

Long-Term Debt to Total Capital

49.98

Officers and Executives

Name Age Officer Since Title
Dr. Pascal Soriot 60 2012 Chief Executive Officer & Executive Director
Ms. Pam P. Cheng 49 2015 Executive VP-Operations & Information Technology
Dr. Aradhana Sarin 46 2021 Chief Financial Officer & Executive Director
Dr. Henry D. Cremisi - - Medical Director
Dr. Hasan Jafri - - Senior Medical Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/azn

MarketWatch News on AZN

  1. London stocks slide amid Evergrande crisis and mining worries

    59 min ago

    - Barbara Kollmeyer

  2. AstraZeneca Stock Climbs on ‘Groundbreaking’ Breast Cancer Drug Trial Results

    8:40 a.m. Today

    - Callum Keown

  3. Moderna Inc. stock underperforms Friday when compared to competitors

    4:31 p.m. Sept. 17, 2021

    - MarketWatch Automation

  4. How a Covid Vaccine Could Lift Sanofi’s Stock

    7:58 a.m. Sept. 17, 2021

    - Pierre Briancon

  5. Moderna Inc. stock rises Thursday, outperforms market

    4:31 p.m. Sept. 16, 2021

    - MarketWatch Automation

  6. Moderna Inc. stock outperforms competitors on strong trading day

    4:31 p.m. Sept. 15, 2021

    - MarketWatch Automation

  7. Moderna Inc. stock outperforms competitors on strong trading day

    4:31 p.m. Sept. 14, 2021

    - MarketWatch Automation

  8. Moderna Inc. stock underperforms Monday when compared to competitors

    4:31 p.m. Sept. 13, 2021

    - MarketWatch Automation

  9. The U.K. Canceled a Vaccine Deal. Here's the Fallout for Stocks.

    9:32 a.m. Sept. 13, 2021

    - Josh Nathan-Kazis

  10. Moderna Inc. stock falls Friday, underperforms market

    4:31 p.m. Sept. 10, 2021

    - MarketWatch Automation

  11. Moderna Inc. stock rises Thursday, outperforms market

    4:31 p.m. Sept. 9, 2021

    - MarketWatch Automation

  12. Moderna Inc. stock underperforms Wednesday when compared to competitors

    4:31 p.m. Sept. 8, 2021

    - MarketWatch Automation

  13. U.S. Covid Deaths Surpass 650,000

    11:10 a.m. Sept. 8, 2021

  14. European stocks slump as worries spread about COVID’s global growth

    9:20 a.m. Sept. 8, 2021

    - Barbara Kollmeyer

  15. Moderna Inc. stock outperforms competitors on strong trading day

    4:31 p.m. Sept. 7, 2021

    - MarketWatch Automation

  16. Moderna Inc. stock outperforms competitors on strong trading day

    4:31 p.m. Sept. 3, 2021

    - MarketWatch Automation

  17. Loading more headlines...
/news/nonmarketwatch/company/us/azn

Other News on AZN

  1. U.S. to allow vaccinated EU citizens into the US - Politico

    10:32 a.m. Today

    - Seeking Alpha

  2. AstraZeneca Breast Cancer Drug Found to Reduce Risk of Dying

    10:06 a.m. Today

    - Denise Roland

  3. AstraZeneca's Enhertu bests Roche's Kadcycla in head-to-head breast cancer trial

    9:28 a.m. Today

    - Seeking Alpha

  4. S&P 500, Bitcoin, Li Auto: What to Watch When the Stock Market Opens Today

    9:13 a.m. Today

    - Caitlin Ostroff

  5. Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe

    8:12 a.m. Today

    - Zacks.com

  6. Covid-19 Vaccine Rollout Falters in Hard-Hit Bulgaria

    6:25 a.m. Today

    - Georgi Kantchev

  7. Here's Why Moderna's Stock Could Crash Before the End of 2021

    7:11 a.m. Sept. 19, 2021

    - Motley Fool

  8. Here's Why Innate Pharma Stock Is Rocketing Higher Today

    1:21 p.m. Sept. 17, 2021

    - Motley Fool

  9. AstraZeneca lung cancer data propel Corvus and Arcus

    10:43 a.m. Sept. 17, 2021

    - Seeking Alpha

  10. Why Moderna and BioNTech Topped the Market Today

    5:29 p.m. Sept. 16, 2021

    - Motley Fool

  11. Loading more headlines...

At a Glance

AstraZeneca Plc

Cambridge Biomedical Campus

1 Francis Crick Avenue

Cambridge, Cambridgeshire CB2 0AA

Phone

44 2037495000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$21.52B

Net Income

$2.49B

2020 Sales Growth

12.6%

Employees

76,100

/news/pressrelease/company/us/azn

Press Releases on AZN

  1. Cancer Immunotherapy Market Key Player SWOT Analysis and Forecast To 2025

    3:34 p.m. July 29, 2021

    - Market Insight Reports

  2. Vaccine Market Expectation Surges with Rising Demand and Changing Trends

    10:33 p.m. July 28, 2021

    - Market Insight Reports

  3. Loading more headlines...
Link to MarketWatch's Slice.